Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib With DA-EPOCH-R or R-CHOP for Untreated DLBCL
NCT04002947Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2019
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Started Aug 2019; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04002947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04002947.